similar product being available OTC? (72 FR 53711 at 53722)

We consulted with FDA's Nonprescription Drugs Advisory Committee and Pulmonary and Allergy Drugs Advisory Committee at a joint meeting held on January 24, 2006, to discuss the essential-use status of MDIs containing epinephrine. During the meeting, several committee members expressed opinions that MDIs containing epinephrine provide important public health benefits to individuals with asthma who face barriers to health care and cannot obtain prescription drugs. You may wish to read the transcript of the joint meeting (available on the Division of Dockets Management Web site (see ADDRESSES)) or the summaries of the discussions at the meeting in the proposed rule (72 FR 53711 at 53716 to 53724).

III. Registration, Agenda, and Transcript

There is no fee to register for the meeting, but registration is required and space is limited. Interested parties are therefore encouraged to register early. Limited visitor parking is available for a fee, and the Twinbrook Metro Stop is within walking distance of the meeting site. Early arrival is encouraged, as there will be security screening. You will be asked for government-issued picture identification by the security officers. If you need special accommodations due to a disability, please include this information when registering.

Registration for General Attendees. Registration is required to attend the public meeting. If you wish to attend the meeting, you must register by November 23, 2007, via e-mail to: *CDEREXSEC@fda.hhs.gov.* Please indicate "Essential-Use Designation of Epinephrine" in the SUBJECT line and provide complete contact information for each attendee (including name, title, affiliation, e-mail address, and phone number(s)). Upon receipt and review for adequacy of information, an e-mail will be sent to confirm registration.

Registration for Speaking Attendees. If you wish to speak at the meeting, you must register by November 23, 2007, via e-mail to: *CDEREXSEC@fda.hhs.gov*. Please indicate "Speaker--Essential Use-Designation of Epinephrine" in the SUBJECT line. When registering, speakers must provide the following information: (1) The topic or issue to be addressed; (2) the speaker's name, title, company or organization, address, phone number, and e-mail address; and (3) the approximate length of time requested to speak. We encourage consolidation of like-minded presentations to enable a broad range of views to be presented.

Agenda and Transcript. The agenda for the public meeting will be available on FDA's Center for Drug Evaluation and Research (CDER) Web site at: http:// www.fda.gov/cder/meeting/ ozone2007.htm. After the meeting, the agenda, presentations, and transcript will be placed on file in the Division of Dockets Management under Docket No. 2007N–0262 and on CDER's Web site identified previously.

Copies of the transcript may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 6–30, Rockville, MD 20857, approximately 20 working days after the meeting at a cost of 10 cents per page, or on compact disc at a cost of \$14.25 each. You may also examine the transcript at the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and on the Internet at *http://www.fda.gov/ohrms/ dockets/default.htm*.

IV. Extension of the Comment Period for the Proposed Rule

FDA is extending the comment period for the proposed rule to December 19, 2007. We believe that extending the comment period is reasonable to accommodate the public meeting and to provide a short period after the meeting to receive additional comments.

V. Request for Comments

Regardless of your attendance at the meeting, you may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments related to the proposed rule (see **DATES**). All relevant data and information should be submitted with the written comments. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one copy. Comments are to be identified with Docket No. 2007N-0262. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Dated: November 5, 2007.

Jeffrey Shuren,

Assistant Commissioner for Policy. [FR Doc. 07–5593 Filed 11–5–07; 4:01 pm] BILLING CODE 4160–01–S

DEPARTMENT OF THE TREASURY

Internal Revenue Service

26 CFR Part 1

[REG-140206-06]

RIN-1545-BF93

Withholding Procedure Under Section 1441 for Certain Distributions to Which Section 302 Applies; Correction

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Correction to notice of proposed rulemaking.

SUMMARY: This document contains corrections to proposed regulations (REG-140206-06) that were published in the **Federal Register** on Wednesday, October 17, 2007 (72 FR 58781) regarding a withholding agent's obligation to withhold and report tax under Chapter 3 of the Internal Revenue Code when there is a distribution in redemption of stock of a corporation that is actively traded on an established financial market.

FOR FURTHER INFORMATION CONTACT:

Kathryn Holman at (202) 622–3840 (not a''.

SUPPLEMENTARY INFORMATION:

Background

The notice of proposed rulemaking (REG-140206-06) that is the subject of this correction is under section 1441 of the Internal Revenue Code.

Need for Correction

As published, this notice of proposed rulemaking (REG-140206-06) contains an error that may prove to be misleading and is in need of clarification.

Correction of Publication

Accordingly, the notice of proposed rulemaking (REG–140206–06) that was the subject of FR Doc. E7–20504 is corrected as follows:

On page 58781, column 3, in the preamble, under the caption "FOR FURTHER INFORMATION CONTACT:", line 2, the language "Kathryn Holman, (202) 622–3440 (not a" is corrected to read "Kathryn Holman, (202) 622–3840 (not a)".

Cynthia Grigsby,

Senior Federal Register Liaison, Publications and Regulations Branch, Legal Processing Division, Associate Chief Counsel (Procedure and Administration).

[FR Doc. E7–21904 Filed 11–7–07; 8:45 am] BILLING CODE 4830–01–P